Who
Barbara G. McClung
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Caribou Biosciences.
In numbers
- Trades disclosed
- 25
- Buys
- 2
- Sells
- 2
- Bought
- $41K
- Sold
- $32K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 20 Oct 2021
- Last trade
- 24 Feb 2026
- Last filed
- 24 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Feb 2026filed 24 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Sold | $14K6,938 at $1.96 | filing |
| 24 Feb 2026filed 24 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Sold | $14K6,938 at $1.96 | filing |
| 20 Feb 2026filed 24 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —202,500 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —202,500 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 21 Feb 2025filed 21 Feb 2025 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Sold | $4,8113,564 at $1.35 | filing |
| 20 Feb 2025filed 21 Feb 2025 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —170,000 at $0.00 | filing |
| 20 Feb 2025filed 21 Feb 2025 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 20 Feb 2024filed 22 Feb 2024 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —153,000 at $0.00 | filing |
| 20 Feb 2024filed 22 Feb 2024 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code A | —33,000 at $0.00 | filing |
| 21 Feb 2023filed 23 Feb 2023 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —131,000 at $0.00 | filing |
| 15 Sep 2022filed 16 Sep 2022 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —77 at $0.00 | filing |
| 15 Sep 2022filed 16 Sep 2022 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,518 at $0.00 | filing |
| 15 Sep 2022filed 16 Sep 2022 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code M | $20777 at $2.69 | filing |
| 15 Sep 2022filed 16 Sep 2022 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Code M | $74K27,518 at $2.69 | filing |
| 20 Dec 2021filed 21 Dec 2021 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —147,000 at $0.00 | filing |
| 7 Dec 2021filed 8 Dec 2021 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code X | —12 at $0.00 | filing |
| 7 Dec 2021filed 8 Dec 2021 | CRBU Caribou Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code X | —6,115 at $0.00 | filing |
| 7 Dec 2021filed 8 Dec 2021 | CRBU Caribou BiosciencesBiotechnology | SEC FORM 4 Bought | $3212 at $2.69 | filing |
News
Caribou Biosciences, Inc. (NASDAQ:CRBU) Stock Has Average Price Target of $5.50CRBU · dailypolitical.com · 19 Oct 2026Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)CRBU · tickerreport.com · 14 Oct 2026Caribou Biosciences Halts Off-the-Shelf CRISPR CAR-T Programs for Lymphoma and Myeloma After Failing to Fund Phase 3 TrialCRBU · medicaldaily.com · 10 Oct 2026
0 headlines in the last 90 days name Barbara G. McClung; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.